Animal models of multiple endocrine neoplasia

Molecular and Cellular Endocrinology

Volumn 421, Issue , 2016, Pages 49-59

  Wiedemann, Tobias ^a   Pellegata, Natalia S ^a  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

Author keywords

Endocrine neoplasia; Endocrine tumors; Menin; Multiple endocrine neoplasia syndromes; P27; Ret

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 1B; CDKN1B PROTEIN, RAT; MEN1 PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN RET; RET PROTEIN, MOUSE;

ARTICLE; CARCINOGENESIS; CDKN1B GENE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HUMAN; MEN1 GENE; MEN1 SYNDROME; MEN2A SYNDROME; MEN2B SYNDROME; MEN4 SYNDROME; MULTIPLE ENDOCRINE NEOPLASIA; NONHUMAN; ONCOGENE; PATHOPHYSIOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN FUNCTION; ANIMAL; FEMALE; GENETIC PREDISPOSITION; GENETICS; MALE; MOUSE; PATHOLOGY; RAT; VETERINARY;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P27; DISEASE MODELS, ANIMAL; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MICE; MULTIPLE ENDOCRINE NEOPLASIA; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-RET; RATS;

EID: 84953639453     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2015.07.004     Document Type: Article

References (79)

1. Acton D.S., Velthuyzen D., Lips C.J., Hoppener J.W. Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene 2000, 19:3121-3125.
2. Bassett J.H., Rashbass P., Harding B., Forbes S.A., Pannett A.A., Thakker R.V. Studies of the murine homolog of the multiple endocrine neoplasia type 1 (MEN1) gene, men1. J. Bone Min. Res. 1999, 14:3-10.
3. Bertolino P., Radovanovic I., Casse H., Aguzzi A., Wang Z.Q., Zhang C.X. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech. Dev. 2003, 120:549-560.
4. Bertolino P., Tong W.M., Galendo D., Wang Z.Q., Zhang C.X. Heterozygous Men1 mutant mice develop a range of endocrine tumors mimicking multiple endocrine neoplasia type 1. Mol. Endocrinol. 2003, 17:1880-1892.
5. Bertolino P., Tong W.M., Herrera P.L., Casse H., Zhang C.X., Wang Z.Q. Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. Cancer Res. 2003, 63:4836-4841.
6. Biondi C.A., Gartside M.G., Waring P., Loffler K.A., Stark M.S., Magnuson M.A., Kay G.F., Hayward N.K. Conditional inactivation of the MEN1 gene leads to pancreatic and pituitary tumorigenesis but does not affect normal development of these tissues. Mol. Cell Biol. 2004, 24:3125-3131.
7. Calender A., Giraud S., Cougard P., Chanson P., Lenoir G., Murat A., Hamon P., Proye C. Multiple endocrine neoplasia type 1 in France: clinical and genetic studies. J. Intern. Med. 1995, 238:263-268.
8. Carlson K.M., Dou S., Chi D., Scavarda N., Toshima K., Jackson C.E., Wells S.A., Goodfellow P.J., Donis-Keller H. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc. Natl. Acad. Sci. U. S. A. 1994, 91:1579-1583.
9. Chandrasekharappa S.C., Guru S.C., Manickam P., Olufemi S.E., Collins F.S., Emmert-Buck M.R., Debelenko L.V., Zhuang Z., Lubensky I.A., Liotta L.A., et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997, 276:404-407.
10. Colombo C., Verga U., Mian C., Ferrero S., Perrino M., Vicentini L., Dazzi D., Opocher G., Pelizzo M.R., Beck-Peccoz P., et al. Comparison of calcium and pentagastrin tests for the diagnosis and follow-up of medullary thyroid cancer. J. Clin. Endocrinol. metabolism 2012, 97:905-913.
11. Crabtree J.S., Scacheri P.C., Ward J.M., Garrett-Beal L., Emmert-Buck M.R., Edgemon K.A., Lorang D., Libutti S.K., Chandrasekharappa S.C., Marx S.J., et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:1118-1123.
12. Crabtree J.S., Scacheri P.C., Ward J.M., McNally S.R., Swain G.P., Montagna C., Hager J.H., Hanahan D., Edlund H., Magnuson M.A., et al. Of mice and MEN1: insulinomas in a conditional mouse knockout. Mol. Cell Biol. 2003, 23:6075-6085.
13. Decker R.A. Expression of papillary thyroid carcinoma in multiple endocrine neoplasia type 2A. Surgery 1993, 114:1059-1063.
14. DeLellis R.A. Multiple endocrine neoplasia syndromes revisited. Clinical, morphologic, and molecular features. Lab. Invest 1995, 72:494-505.
15. Donis-Keller H., Dou S., Chi D., Carlson K.M., Toshima K., Lairmore T.C., Howe J.R., Moley J.F., Goodfellow P., Wells S.A. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum. Mol. Genet. 1993, 2:851-856.
16. Eng C., Clayton D., Schuffenecker I., Lenoir G., Cote G., Gagel R.F., van Amstel H.K., Lips C.J., Nishisho I., Takai S.I., et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. Jama 1996, 276:1575-1579.
17. Frank-Raue K., Hoppner W., Frilling A., Kotzerke J., Dralle H., Haase R., Mann K., Seif F., Kirchner R., Rendl J., et al. Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German medullary thyroid carcinoma study group. J. Clin. Endocrinol. Metab. 1996, 81:1780-1783.
18. Fritz A., Walch A., Piotrowska K., Rosemann M., Schaffer E., Weber K., Timper A., Wildner G., Graw J., Hofler H., et al. Recessive transmission of a multiple endocrine neoplasia syndrome in the rat. Cancer Res. 2002, 62:3048-3051.
19. Gaertner F.C., Wiedemann T., Yousefi B.H., Lee M., Repokis I., Higuchi T., Nekolla S.G., Yu M., Robinson S., Schwaiger M., et al. Preclinical evaluation of 18F-LMI1195 for in vivo imaging of pheochromocytoma in the MENX tumor model. J. Nucl. Med. 2013, 54:2111-2117.
20. Gestblom C., Sweetser D.A., Doggett B., Kapur R.P. Sympathoadrenal hyperplasia causes renal malformations in Ret(MEN2B)-transgenic mice. Am. J. Pathol. 1999, 155:2167-2179.
21. Guru S.C., Crabtree J.S., Brown K.D., Dunn K.J., Manickam P., Prasad N.B., Wangsa D., Burns A.L., Spiegel A.M., Marx S.J., et al. Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene. Mamm. Genome 1999, 10:592-596.
22. Harding B., Lemos M.C., Reed A.A., Walls G.V., Jeyabalan J., Bowl M.R., Tateossian H., Sullivan N., Hough T., Fraser W.D., et al. Multiple endocrine neoplasia type 1 knockout mice develop parathyroid, pancreatic, pituitary and adrenal tumours with hypercalcaemia, hypophosphataemia and hypercorticosteronaemia. Endocr. Relat. Cancer 2009, 16:1313-1327.
23. Havekes B., Lai E.W., Corssmit E.P., Romijn J.A., Timmers H.J., Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q. J. Nucl. Med. Mol. Imaging 2008, 52:419-429.
24. Hoegerle S., Nitzsche E., Altehoefer C., Ghanem N., Manz T., Brink I., Reincke M., Moser E., Neumann H.P. Pheochromocytomas: detection with 18F DOPA whole body PET-initial results. Radiology 2002, 222:507-512.
25. Hofstra R.M., Landsvater R.M., Ceccherini I., Stulp R.P., Stelwagen T., Luo Y., Pasini B., Hoppener J.W., van Amstel H.K., Romeo G., et al. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-376.
26. Jensen R.T., Berna M.J., Bingham D.B., Norton J.A. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008, 113:1807-1843.
27. Kapur R.P., Hoyle G.W., Mercer E.H., Brinster R.L., Palmiter R.D. Some neuronal cell populations express human dopamine beta-hydroxylase-lacZ transgenes transiently during embryonic development. Neuron 1991, 7:717-727.
28. Larsson C., Skogseid B., Oberg K., Nakamura Y., Nordenskjold M. Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature 1988, 332:85-87.
29. Lee M., Marinoni I., Irmler M., Psaras T., Honegger J.B., Beschorner R., Anastasov N., Beckers J., Theodoropoulou M., Roncaroli F., et al. Transcriptome analysis of MENX-associated rat pituitary adenomas identifies novel molecular mechanisms involved in the pathogenesis of human pituitary gonadotroph adenomas. Acta Neuropathol. 2013, 126:137-150.
30. Lee M., Theodoropoulou M., Graw J., Roncaroli F., Zatelli M.C., Pellegata N.S. Levels of p27 sensitize to dual PI3K/mTOR inhibition. Mol. Cancer Ther. 2011, 10:1450-1459.
31. Lee M., Wiedemann T., Gross C., Leinhauser I., Roncaroli F., Braren R., Pellegata N.S. Targeting PI3K/mTOR signaling displays potent antitumor efficacy against nonfunctioning pituitary adenomas. Clin. Cancer Res. 2015, 21:3204-3215.
32. Lemos M.C., Harding B., Reed A.A., Jeyabalan J., Walls G.V., Bowl M.R., Sharpe J., Wedden S., Moss J.E., Ross A., et al. Genetic background influences embryonic lethality and the occurrence of neural tube defects in Men1 null mice: relevance to genetic modifiers. J. Endocrinol. 2009, 203:133-142.
33. Lemos M.C., Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1): analysis of 1336 mutations reported in the first decade following identification of the gene. Hum. Mutat. 2008, 29:22-32.
34. Libutti S.K., Crabtree J.S., Lorang D., Burns A.L., Mazzanti C., Hewitt S.M., O'Connor S., Ward J.M., Emmert-Buck M.R., Remaley A., et al. Parathyroid gland-specific deletion of the mouse Men1 gene results in parathyroid neoplasia and hypercalcemic hyperparathyroidism. Cancer Res. 2003, 63:8022-8028.
35. Lodewijk L., Bongers P.J., Kist J.W., Conemans E.B., de Laat J.M., Pieterman C.R., van der Horst-Schrivers A.N., Jorna C., Hermus A.R., Dekkers O.M., et al. Thyroid incidentalomas in patients with multiple endocrine neoplasia type 1. Eur. J. Endocrinol. 2015, 172:337-342.
36. Loffler K.A., Biondi C.A., Gartside M., Waring P., Stark M., Serewko-Auret M.M., Muller H.K., Hayward N.K., Kay G.F. Broad tumor spectrum in a mouse model of multiple endocrine neoplasia type 1. Int. J. Cancer 2007, 120:259-267.
37. Lorenzo M.J., Gish G.D., Houghton C., Stonehouse T.J., Pawson T., Ponder B.A., Smith D.P. RET alternate splicing influences the interaction of activated RET with the SH2 and PTB domains of Shc, and the SH2 domain of Grb2. Oncogene 1997, 14:763-771.
38. Lu J., Herrera P.L., Carreira C., Bonnavion R., Seigne C., Calender A., Bertolino P., Zhang C.X. Alpha cell-specific Men1 ablation triggers the transdifferentiation of glucagon-expressing cells and insulinoma development. Gastroenterology 2010, 138:1954-1965.
39. Lubensky I.A., Debelenko L.V., Zhuang Z., Emmert-Buck M.R., Dong Q., Chandrasekharappa S., Guru S.C., Manickam P., Olufemi S.E., Marx S.J., et al. Allelic deletions on chromosome 11q13 in multiple tumors from individual MEN1 patients. Cancer Res. 1996, 56:5272-5278.
40. Marinoni I., Lee M., Mountford S., Perren A., Bravi I., Jennen L., Feuchtinger A., Drouin J., Roncaroli F., Pellegata N.S. Characterization of MENX-associated pituitary tumours. Neuropathol. Appl. Neurobiol. 2013, 39:256-269.
41. Marshall G.M., Peaston A.E., Hocker J.E., Smith S.A., Hansford L.M., Tobias V., Norris M.D., Haber M., Smith D.P., Lorenzo M.J., et al. Expression of multiple endocrine neoplasia 2B RET in neuroblastoma cells alters cell adhesion in vitro, enhances metastatic behavior in vivo, and activates Jun kinase. Cancer Res. 1997, 57:5399-5405.
42. Martiniova L., Cleary S., Lai E.W., Kiesewetter D.O., Seidel J., Dawson L.F., Phillips J.K., Thomasson D., Chen X., Eisenhofer G., et al. Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma. Nucl. Med. Biol. 2012, 39:215-226.
43. Marx S.J. Molecular genetics of multiple endocrine neoplasia types 1 and 2. Nat. Rev. Cancer 2005, 5:367-375.
44. Mercer E.H., Hoyle G.W., Kapur R.P., Brinster R.L., Palmiter R.D. The dopamine beta-hydroxylase gene promoter directs expression of E. coli lacZ to sympathetic and other neurons in adult transgenic mice. Neuron 1991, 7:703-716.
45. Michiels F.M., Chappuis S., Caillou B., Pasini A., Talbot M., Monier R., Lenoir G.M., Feunteun J., Billaud M. Development of medullary thyroid carcinoma in transgenic mice expressing the RET protooncogene altered by a multiple endocrine neoplasia type 2A mutation. Proc. Natl. Acad. Sci. U. S. A. 1997, 94:3330-3335.
46. Miederer M., Molatore S., Marinoni I., Perren A., Spitzweg C., Reder S., Wester H.J., Buck A.K., Schwaiger M., Pellegata N.S. Functional imaging of pheochromocytoma with Ga-DOTATOC and c-HED in a genetically defined rat model of multiple endocrine neoplasia. Int. J. Mol. Imaging 2011, 2011:175352.
47. Molatore S., Kiermaier E., Jung C.B., Lee M., Pulz E., Hofler H., Atkinson M.J., Pellegata N.S. Characterization of a naturally-occurring p27 mutation predisposing to multiple endocrine tumors. Mol. Cancer 2010, 9:116.
48. Molatore S., Liyanarachchi S., Irmler M., Perren A., Mannelli M., Ercolino T., Beuschlein F., Jarzab B., Wloch J., Ziaja J., et al. Pheochromocytoma in rats with multiple endocrine neoplasia (MENX) shares gene expression patterns with human pheochromocytoma. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18493-18498.
49. Molatore S., Pellegata N.S. The MENX syndrome and p27: relationships with multiple endocrine neoplasia. Prog. Brain Res. 2010, 182:295-320.
50. Mulligan L.M., Marsh D.J., Robinson B.G., Schuffenecker I., Zedenius J., Lips C.J., Gagel R.F., Takai S.I., Noll W.W., Fink M., et al. Genotype-phenotype correlation in multiple endocrine neoplasia type 2: report of the international RET mutation consortium. J. Intern. Med. 1995, 238:343-346.
51. Myers S.M., Eng C., Ponder B.A., Mulligan L.M. Characterization of RET proto-oncogene 3' splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995, 11:2039-2045.
52. Oishi S., Sato T., Takiguchi-Shirahama S., Nakamura Y. Mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (Sipple's syndrome). Endocr. J. 1995, 42:527-536.
53. Pellegata N.S., Quintanilla-Martinez L., Siggelkow H., Samson E., Bink K., Hofler H., Fend F., Graw J., Atkinson M.J. Germ-line mutations in p27Kip1 cause a multiple endocrine neoplasia syndrome in rats and humans. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:15558-15563.
54. Piotrowska K., Pellegata N.S., Rosemann M., Fritz A., Graw J., Atkinson M.J. Mapping of a novel MEN-like syndrome locus to rat chromosome 4. Mamm. Genome 2004, 15:135-141.
55. Raue F., Frank-Raue K. Update multiple endocrine neoplasia type 2. Fam. Cancer 2010, 9:449-457.
56. Reynolds L., Jones K., Winton D.J., Cranston A., Houghton C., Howard L., Ponder B.A., Smith D.P. C-cell and thyroid epithelial tumours and altered follicular development in transgenic mice expressing the long isoform of MEN 2A RET. Oncogene 2001, 20:3986-3994.
57. Romei C., Pardi E., Cetani F., Elisei R. Genetic and clinical features of multiple endocrine neoplasia types 1 and 2. J. Oncol. 2012, 2012:705036.
58. Rossel M., Pasini A., Chappuis S., Geneste O., Fournier L., Schuffenecker I., Takahashi M., van Grunsven L.A., Urdiales J.L., Rudkin B.B., et al. Distinct biological properties of two RET isoforms activated by MEN 2A and MEN 2B mutations. Oncogene 1997, 14:265-275.
59. Santoro M., Carlomagno F., Romano A., Bottaro D.P., Dathan N.A., Grieco M., Fusco A., Vecchio G., Matoskova B., Kraus M.H., et al. Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 1995, 267:381-383.
60. Scacheri P.C., Crabtree J.S., Novotny E.A., Garrett-Beal L., Chen A., Edgemon K.A., Marx S.J., Spiegel A.M., Chandrasekharappa S.C., Collins F.S. Bidirectional transcriptional activity of PGK-neomycin and unexpected embryonic lethality in heterozygote chimeric knockout mice. Genesis 2001, 30:259-263.
61. Scarsbrook A.F., Thakker R.V., Wass J.A., Gleeson F.V., Phillips R.R. Multiple endocrine neoplasia: spectrum of radiologic appearances and discussion of a multitechnique imaging approach. Radiographics 2006, 26:433-451.
62. Schussheim D.H., Skarulis M.C., Agarwal S.K., Simonds W.F., Burns A.L., Spiegel A.M., Marx S.J. Multiple endocrine neoplasia type 1: new clinical and basic findings. Trends Endocrinol. Metab. 2001, 12:173-178.
63. Scoazec J.Y. Angiogenesis in neuroendocrine tumors: therapeutic applications. Neuroendocrinology 2013, 97:45-56.
64. Shen H.C., He M., Powell A., Adem A., Lorang D., Heller C., Grover A.C., Ylaya K., Hewitt S.M., Marx S.J., et al. Recapitulation of pancreatic neuroendocrine tumors in human multiple endocrine neoplasia type I syndrome via Pdx1-directed inactivation of Men1. Cancer Res. 2009, 69:1858-1866.
65. Shen H.C., Ylaya K., Pechhold K., Wilson A., Adem A., Hewitt S.M., Libutti S.K. Multiple endocrine neoplasia type 1 deletion in pancreatic alpha-cells leads to development of insulinomas in mice. Endocrinology 2010, 151:4024-4030.
66. Shyla A., Holzlwimmer G., Calzada-Wack J., Bink K., Tischenko O., Guilly M.N., Chevillard S., Samson E., Graw J., Atkinson M.J., et al. Allelic loss of chromosomes 8 and 19 in MENX-associated rat pheochromocytoma. Int. J. Cancer 2010, 126:2362-2372.
67. Smith-Hicks C.L., Sizer K.C., Powers J.F., Tischler A.S., Costantini F. C-cell hyperplasia, pheochromocytoma and sympathoadrenal malformation in a mouse model of multiple endocrine neoplasia type 2B. EMBO J. 2000, 19:612-622.
68. Stewart C., Parente F., Piehl F., Farnebo F., Quincey D., Silins G., Bergman L., Carle G.F., Lemmens I., Grimmond S., et al. Characterization of the mouse Men1 gene and its expression during development. Oncogene 1998, 17:2485-2493.
69. Sweetser D.A., Froelick G.J., Matsumoto A.M., Kafer K.E., Marck B., Palmiter R.D., Kapur R.P. Ganglioneuromas and renal anomalies are induced by activated RET(MEN2B) in transgenic mice. Oncogene 1999, 18:877-886.
70. Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1). Best. Pract. Res. Clin. Endocrinol. Metab. 2010, 24:355-370.
71. Thakker R.V. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol. Cell Endocrinol. 2014, 386:2-15.
72. Thakker R.V., Newey P.J., Walls G.V., Bilezikian J., Dralle H., Ebeling P.R., Melmed S., Sakurai A., Tonelli F., Brandi M.L., et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012, 97:2990-3011.
73. Theodoropoulou M., Stalla G.K. Somatostatin receptors: from signaling to clinical practice. Front. Neuroendocrinol. 2013, 34:228-252.
74. Trump D., Farren B., Wooding C., Pang J.T., Besser G.M., Buchanan K.D., Edwards C.R., Heath D.A., Jackson C.E., Jansen S., et al. Clinical studies of multiple endocrine neoplasia type 1 (MEN1). QJM 1996, 89:653-669.
75. Vasen H.F., van der Feltz M., Raue F., Kruseman A.N., Koppeschaar H.P., Pieters G., Seif F.J., Blum W.F., Lips C.J. The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases. Archives Intern. Med. 1992, 152:1250-1252.
76. Veniaminova N.A., Hayes M.M., Varney J.M., Merchant J.L. Conditional deletion of menin results in antral G cell hyperplasia and hypergastrinemia. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 303:G752-G764.
77. Vierimaa O., Ebeling T.M., Kytola S., Bloigu R., Eloranta E., Salmi J., Korpi-Hyovalti E., Niskanen L., Orvola A., Elovaara E., et al. Multiple endocrine neoplasia type 1 in northern Finland clinical features and genotype phenotype correlation. Eur. J. Endocrinol. 2007, 157:285-294.
78. Walls G.V. Multiple endocrine neoplasia (MEN) syndromes. Semin. Pediatr. Surg. 2014, 23:96-101.
79. Win Z., Al-Nahhas A., Towey D., Todd J.F., Rubello D., Lewington V., Gishen P. 68Ga-DOTATATE PET in neuroectodermal tumours: first experience. Nucl. Med. Commun. 2007, 28:359-363.